Authors
Latest:
Cytoreductive Surgery and HIPEC for Peritoneal CarcinomatosisThe management of patients with malignant peritoneal surface disease (PSD) commonly known as "carcinomatosis" continues to evolve.
Latest:
Dr. Stadtmauer on the Evolving Treatment Landscape in Multiple MyelomaEdward A. Stadtmauer, MD, discusses the evolving treatment landscape in multiple myeloma.
Latest:
Dr. Garon on the Role of Trastuzumab Deruxtecan in Lung CancerEdward B. Garon, MD, discusses remaining questions with fam-trastuzumab deruxtecan-nxki in the field of lung cancer.
Latest:
Key Takeaways and Closing Thoughts on ADCsExperts discuss key takeaways and closing thoughts on antibody-drug conjugates (ADCs) in cancer treatment.
Latest:
Dr. Bradley on OX40 for the Treatment of CancerEdward Bradley, MD, from MedImmune (the global biologics research and development arm of AstraZeneca), describes the development of an agonist for the treatment of cancer.
Latest:
Dr Garon on Considerations for Perioperative Immunotherapy Use in Lung CancerEdward B. Garon, MD, MS, discusses key considerations when selecting an optimal perioperative treatment approach for patients with lung cancer.
Latest:
Managing Toxicities in Short- and Long-Term Treatment with ADCsVijayakrishna Gadi, MD, PhD, discusses short-term and long-term treatments with ADCs.
Latest:
More Progress Needed to Bring Oncology Practice Into the Digital Health AgeMuch needs to be done to improve interoperability of medical data systems. However, standards and new systems are developing at a rapid pace, affording advantages and efficiencies where, previously, enormous impediments stood in the way.
Latest:
Dr. Kim on the Role of Biomarker Testing in Treatment Decisions for Solid TumorsEdward S. Kim, MD, MBA, discusses the role of biomarker testing in making treatment decisions for patients with solid tumors.
Latest:
Recent Progress in the Prostate Cancer Treatment LandscapeKey opinion leaders provide a broad perspective on recent shifts in the treatment landscape for prostate cancer.
Latest:
IO Therapy in mCRPC and Clinical PearlsBefore sharing clinical pearls for the treatment of prostate cancer, key opinion leaders reflect on the potential use of immune checkpoint inhibitors in mCRPC.
Latest:
CLL: Final ThoughtsAn expert panel provides their final thoughts about the future of the chronic lymphocytic leukemia (CLL) treatment landscape.
Latest:
Dr. Connolly on Potential Benefit of Postmastectomy Radiation for Breast CancerEileen Connolly, MD, PhD, discusses the possible benefit of postmastectomy radiation for patients with breast cancer.
Latest:
Celebrating Life and Liberty: 3rd Annual Survivorship EventWith the Statue of Liberty as a symbolic backdrop, nearly 2200 cancer patients, caregivers, and healthcare professionals recently gathered at the 3rd Annual 'Celebrating Life and Liberty' survivorship event.
Latest:
PALB2 Mutations Confer Susceptibility to Familial Pancreatic Cancer and May Provide a Novel Targeted Therapeutic Approach to CancerGermline mutations in PALB2 have recently been shown to increase lifetime risk of pancreatic cancer and breast cancer, among other types.
Latest:
Dr. O'Reilly on Veliparib/Chemotherapy Triplet in Germline BRCA/PALB2+ Pancreatic CancerEileen M. O’Reilly, MD, discusses the randomized phase II trial of gemcitabine and cisplatin versus gemcitabine and cisplatin and veliparib in patients with pancreas adenocarcinoma harboring a known germline BRCA or PALB2 mutation, which was presented at the 2020 Gastrointestinal Cancers Symposium.
Latest:
Dr O'Reilly on Survival Outcomes of the NAPOLI 3 trial in Metastatic PDACEileen M. O'Reilly, MD, discusses survival outcomes from the phase 3 NAPOLI 3 trial in patients with metastatic pancreatic ductal adenocarcinoma.
Latest:
Dr. O'Reilly on the Potential Role of Veliparib in Pancreatic CancerEileen O'Reilly, MD, discusses the potential role of veliparib in pancreatic cancer.
Latest:
Dr. O'Reilly on the Role of Germline Testing in Pancreatic CancerEileen O'Reilly, MD, discusses germline testing in pancreatic cancer.
Latest:
Dr. Kirson Discusses the LUNAR Study in Advanced NSCLCEilon Kirson, MD, PhD, chief medical officer, Novocure, discusses the LUNAR study in advanced non–small cell lung cancer.
